278 related articles for article (PubMed ID: 8834170)
1. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
3. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
4. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
5. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
[TBL] [Abstract][Full Text] [Related]
6. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
Pollock PM; Yu F; Qiu L; Parsons PG; Hayward NK
Oncogene; 1995 Aug; 11(4):663-8. PubMed ID: 7651729
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
8. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
Caldas C; Hahn SA; da Costa LT; Redston MS; Schutte M; Seymour AB; Weinstein CL; Hruban RH; Yeo CJ; Kern SE
Nat Genet; 1994 Sep; 8(1):27-32. PubMed ID: 7726912
[TBL] [Abstract][Full Text] [Related]
9. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
[TBL] [Abstract][Full Text] [Related]
12. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
13. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
14. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
Luca M; Xie S; Gutman M; Huang S; Bar-Eli M
Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563
[TBL] [Abstract][Full Text] [Related]
18. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
19. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
[TBL] [Abstract][Full Text] [Related]
20. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
